粒细胞集落刺激因子治疗乙型肝炎相关慢加急性肝衰竭随机对照临床研究

目的评价重组人粒细胞集落刺激因子(recombinant granulocyte-colony stimulating factor,r G-CSF)治疗乙型肝炎相关慢加急性肝衰竭(hepatitis B virus-associated acute-on-chronic liver failure,HBV-ACLF)的有效性和安全性。方法将99例ACLF患者随机分为2组,试验组49例,对照组50例。对照组给予内科综合治疗,试验组在综合治疗基础上接受r G-CSF300μg,1次/d,皮下注射,共计6针,然后减量至隔日1次,共6次,总计12针。结果生存分析表明,试验组治疗1月、3月的生存率分别为91.3%和72.9%,大于对照组的63.7%和50.0%(P<0.05)。治疗期间无严重不良反应发生。结论r G-CSF能够显著提高HBV-ACLF患者的生存率,并且有较高的安全性。

The clinical trial of rG-CSF for hepatitis B virus-associated acute-on-chronic liver failure

Objective To evaluate the safety and efficiacy of rG-CSF on patients with hepatitis B virus-associated acute-on-chronic liver failure (ACLF). Methods A total of 99 cases of ACLF were randomly divided into 2 groups, 49 cases in the experimental group and 50 cases in the control group. The control group was given internal comprehensive treatment while the experimental group on the basis of the internal comprehensive treatment received rG-CSF 300 g, once per day, subcutaneous injection, six injections in total, and then reduced to once every other day, a total of 6 times, 12 injections in total. Results Survival analysis showed that the survival rates of the experimental group in January and March were 91.3% and 72.9% respectively, which were higher than those in the control group of 63.7% and 50% (P < 0.05). There were no serious adverse effects during the treatment period. Conclusions rG-CSF can significantly improve the survival rate of patients with HBV-ACLF with higher security.